Global Ganja Report

Last month, the DEA enthused the pharmaceutical industry but disappointed cannabis advocates by re-scheduling the drug Epidiolex—but not CBD, the cannabinoid that makes it work. Now word emerges of a letter to the DEA by the Food & Drug Administration essentially calling for the descheduling of CBD altogether.

Among several cannabis-related bills signed into law by California's Gov. Jerry Brown was one creating an "equity" program for the state's legalized industry, aimed at justice and inclusion for those communities hardest hit by marijuana prohibition. Another measure will erase past convictions for possession of cannabis in quantities that are now legal.

With the DEA's rescheduling of Epidiolex, shares in the British manufacturer of the drug are soaring. But CBD—the actual cannabinoid that the product is based on—is to remain in the restrictive Scheudle 1.

A Vancouver police raid on a "harm reduction center" that was selling cannabis products raises uneasy questions about the availability of cannabis in British Columbia when Canadian legalization officially hits in next month. With only one retail outfit likely to be licensed province-wide and authorities pledging a crackdown on the old dispensaries, the ironic reality may be cannabis will initially be harder to get in BC once it is "legal."

The global cannabis industry is increasingly dependent on factories in China's industrial zones—and fears being impacted by Trump's trade war with Beijing. Chinese pharmaceutical firms meanwhile explore potential applications of cannabis. Yet possession of herbaceous cannabis can land you before a firing squad in China. Human rights groups express alarm about the furious pace of executions in the People's Republic—outstripping the rest of the world combined. And drug offenses—including pot possession—top the country's capital crimes.

The Green Wolverine conference at the University of Michigan this month will bring speakers from across the country for a symposium on cannabis science. With Michigan facing a legalization initiative this November, the student-organized event is intended, among other things, to help voters make an informed choice.

A bill that would allow use of medical marijuana products in California's schools has arrived on the desk of Gov. Jerry Brown. The legislation would address an inequity in California's medical marijuana program, and is named Jojo's Act after a South San Francisco high school student who suffers from a severe form of epilepsy.

The California State Legislature on Aug. 27 approved a bill to allow students to use medicinal cannabis preparations on K-12 school campuses.

Having just undertaken a "critical study" of CBD, the non-psychoactive cannabinoid held to have multifarious medicinal applications, the World Health Organization is now opening such a study on THC. Stigmatized due to its psychoactive properties and currently in the shadow of the suddenly sexy CBD, tetrahydrocannabinol shows its own potential for application by the medical industry.